Ayala de la Peña, F.Andrés, RaquelGarcia-Saenz, José AngelManso, LuisMargeli, M. E.Dalmau, M. E.Pernas, S.Prat, AleixServitja Tormo, SoniaCiruelos, Eva2019-03-272019-03-272019Ayala de la Peña F, Andrés R, Garcia-Sáenz JA, Manso L, Margelí M, Dalmau E. et al. SEOM clinical guidelines in early stage breast cancer (2018). Clin Transl Oncol. 2019 Jan;21(1):18-30. DOI: 10.1007/s12094-018-1973-61699-048Xhttp://hdl.handle.net/10230/36977Breast cancer is the most common cancer in women in our country and it is usually diagnosed in the early and potentially curable stages. Nevertheless, around 20-30% of patients will relapse despite appropriate locoregional and systemic therapies. A better knowledge of this disease is improving our ability to select the most appropriate therapy for each patient with a recent diagnosis of an early stage breast cancer, minimizing unnecessary toxicities and improving long-term efficacy.application/pdfengThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creative commons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Mama -- Càncerinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1007/s12094-018-1973-6Early breast cancerAdjuvantFollow-upGenomic predictive testNeoadjuvantinfo:eu-repo/semantics/openAccess